Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Research and development activities, with our large research sites in Germany (Biberach), the USA (Ridgefield) and Austria (Vienna), were focused on the following indication areas:
During the past decade from 2003 to 2012, Boehringer Ingelheim conducted or sponsored 1,379 studies with approximately one million patients on 119 substances in 94 countries.
We have nearly 7,500 highly qualified people working in research & development out of more than 46,000 Boehringer Ingelheim employees worldwide.
In 2012, Boehringer Ingelheim posted net sales of 14,7 billion euro while investing almost 23 percent of net sales in our largest business segment Prescription Medicines on research and development.